Jangee

Drospirenone, the active ingredient in Jangee, is a combined oral contraceptive presented as a tablet for oral use. It works together with ethinylestradiol to prevent pregnancy and to help regulate menstrual cycles in women of reproductive age.

GNH USA supplies Jangee as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jangee, a combined oral contraceptive, is used in the hormonal contraception pathway to prevent pregnancy and to manage menstrual cycle disorders.

- Prevention of pregnancy: provides reliable contraceptive protection by inhibiting ovulation. - Regulation of menstrual cycles: helps achieve more predictable bleeding patterns and reduces cycle irregularities. - Management of dysmenorrhea: may lessen menstrual pain and associated premenstrual symptoms.

Oral administration of Jangee may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: temporary swelling or discomfort. - Weight gain: modest increase in body weight. - Mood changes: irritability or mood swings. - Spotting or breakthrough bleeding: irregular light bleeding between periods.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Arterial thrombosis: stroke or myocardial infarction. - Hypertension: significant increase in blood pressure. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Liver dysfunction: jaundice or abnormal liver enzymes.

Before prescribing Jangee, clinicians should consider several precautionary measures to ensure safe use. - Contraindications: avoid in women with a history of thromboembolic disorders, estrogen‑dependent tumors, or active liver disease. - Smoking: do not prescribe to smokers over 35 years of age due to increased cardiovascular risk. - Cardiovascular risk: assess blood pressure and lipid profile before initiation. - Pregnancy testing: confirm non‑pregnant status prior to starting therapy. - Breastfeeding: evaluate risk‑benefit, as estrogen may affect milk production. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Jangee can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may reduce contraceptive effectiveness. - Rifampicin or other strong CYP3A4 inducers: can markedly decrease hormone levels. - St. John’s wort: potent inducer that may lead to contraceptive failure.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may increase hormone concentrations, raising side‑effect risk. - Certain antibiotics (e.g., clarithromycin): can modestly affect hormone metabolism. - Selective serotonin reuptake inhibitors (SSRIs): may increase risk of mood‑related side effects. - Herbal supplements containing phytoestrogens: monitor for additive estrogenic effects.